Collaboration and License Agreements - Additional Information (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2020 USD ($) Target	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Collaboration And License Agreements [Line Items]
Collaboration and license revenue		$ 3,363,000	$ 2,412,000	$ 10,440,000	$ 7,287,000
Incurred costs		19,941,000	$ 18,254,000	58,427,000	41,726,000
Deferred revenue, current portion		5,932,000		5,932,000		$ 11,410,000
Long-term deferred revenue		$ 0		$ 0		$ 1,497,000
Maximum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest		10.00%		10.00%
Minimum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest	10.00%
Novartis
Collaboration And License Agreements [Line Items]
License agreement date	Mar. 31, 2020
Upfront payment received	$ 20,000,000.0
Upfront payment receivable	$ 20,000,000.0
Negotiation period				180 days
Expects research term	3 years
Collaboration and license revenue				$ 10,400,000	7,000,000.0
Incurred costs				3,500,000	$ 2,300,000
Deferred revenue, current portion		$ 5,900,000		5,900,000
Long-term deferred revenue		$ 0		$ 0
Novartis | Maximum
Collaboration And License Agreements [Line Items]
Number of targets identified | Target	3
Novartis | Research Funding
Collaboration And License Agreements [Line Items]
Upfront payment received	$ 10,000,000.0
Upfront payment receivable	$ 10,000,000.0